Reveal by Guardant Health: status and timeline

Milestones

No announced next step

Reveal launched2022Complete.
Acceleration to >100% volume growthQ3 2026Complete.

Spec sheet

Spec	Reveal
Q2 2026 oncology revenue	$219.1M^R (reported)
Q2 2026 oncology test volume	104,000^R (reported)

^R reported by the company

About Guardant Health

The team behind Reveal

Guardant Health

Shield blood test, colorectal cancer screening

Guardant Health develops blood tests for early cancer detection. Shield is the first FDA-approved blood test for colorectal cancer screening. Reveal detects residual disease after cancer treatment. Guardant went public on NASDAQ (GH) in October 2018.

Shield is the first FDA-approved blood test for colorectal cancer screening, with 83% sensitivity.
Q2 2026: 66k tests, $52.9M revenue, 2026 guidance $218-230M.
American Cancer Society, UnitedHealth (40M members), and Medicare cover Shield.

guardanthealth.com (opens guardanthealth.com)Company profile →

Founded: 201214 yrs
Headquarters: United States
Status: Public
Valuation: public
Staff: ~2,506Dec 2025
Works in: BiotechGenomics & sequencing
Coverage: 2 programs · 4 updateslatest 7 Aug 2026checked 11 Oct
Customers: UnitedHealth Group (opens unitedhealthgroup.com)
Partners: Quest Diagnostics (opens questdiagnostics.com)American Cancer Society (opens cancer.org)
People: Helmy Eltoukhy (opens en.wikipedia.org)Co-founder & Co-CEOAmirAli Talasaz (opens guardanthealth.com)Co-founder & Co-CEO